EGFR and neoplasm: In addition, we found that 29.0% (11/38) of patients who have discordant EGFR mutations performed their tumor tissue ARMS-PCR detection at least one months earlier than plasma ddPCR detection, suggesting that the discrepancies may be caused by molecular evolution of tumors.